Bio tech company updates — 6/24/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Korean biotech companies are actively pursuing global partnerships and deals at BIO International Convention 2026 in San Diego, with SK biopharmaceuticals positioning itself as a bridge between Asian and Western markets. However, the sector faces intensifying competition from China's rapid advancement in drug development. Major Korean firms including Lotte Biologics and partnerships with AstraZeneca are on display this week.
Key Findings
Korean biotechnology companies are competing aggressively at BIO International Convention 2026 (June 22–25 in San Diego) to secure partnerships and expand globally, but face mounting pressure from China's accelerating drug development capabilities.
SK biopharmaceuticals is leveraging its U.S. commercialization experience to position itself as a bridge connecting Korean and Asian biotech innovation with the world's largest pharmaceutical market, emphasizing AI and open innovation strategies.

Korean biotechs have strengthened partnerships with AstraZeneca, advancing collaborative efforts in open innovation and technological cooperation at the convention.
Lotte Biologics is showcasing three in-booth presentations, including cooperation with Asimov (a leading cell development organization) and scale-up strategies using computational fluid dynamics technology for manufacturing efficiency and digital transformation.

Details
Competitive Pressure from China
Korea's biotechnology sector confronts a narrowing window of opportunity as China surges ahead in new drug development capabilities. Industry observers note that this competition is intensifying pressure on Korean firms to accelerate their innovation and partnership strategies.
SK Biopharmaceuticals' Strategic Positioning
At a press briefing during BIO 2026, SK biopharmaceuticals emphasized its role as a connector between Korean/Asian biotech innovation and global pharmaceutical markets. The company is leveraging artificial intelligence alongside open innovation frameworks to build this East-West bridge and expand its growth platform.
AstraZeneca Partnership Expansion
Multiple Korean biotechs have bolstered existing collaborations with pharmaceutical giant AstraZeneca, focusing on open innovation and technology cooperation initiatives announced at the San Diego convention.
Lotte Biologics' Technology Showcase
Lotte Biologics is presenting computational fluid dynamics-based scale-up strategies designed to improve manufacturing efficiency and enable digital manufacturing capabilities. The company is also demonstrating partnership potential with Asimov, a recognized leader in cell development technology.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.